Background: Diagnosing centrally located lung tumors without endobronchial abnormalities and not located near the major airways is a diagnostic challenge. Tumors near or adjacent to the esophagus can be aspirated and detected with esophageal ultrasound (EUS) using gastrointestinal endoscopes. Objective: To assess the feasibility and diagnostic yield of endoscopic ultrasound with bronchoscope-guided fine needle aspiration (EUS-B-FNA) in paraesophageally located lung tumors and its added value to bronchoscopy and endobronchial ultrasound (EBUS). Methods: Retrospective, multicenter international study (from January 1, 2015 until January 1, 2018) of patients with suspected lung cancer, undergoing bronchoscopy, EBUS, and endoscopic ultrasound bronchoscopy (EUS-B) in one session by a single operator (pulmonologist), in whom the primary lung tumor was detected and aspirated by EUS-B. In the absence of malignancy following endoscopy, transthoracic ultrasound needle aspiration, clinical and radiological follow-up of at least 6 months was performed. The yield and sensitivity of EUS-B-FNA and its added value to bronchoscopy and EBUS was assessed. Results: 58 patients were identified with the following diagnosis: non-small-cell lung cancer (n = 43), small-cell lung cancer (n = 6), mesothelioma (n = 2), metastasis (n = 1), nonmalignant (n = 6). The yield and sensitivity of EUS-B-FNA for detecting lung cancer was 90%. In 26 patients (45%), the intrapulmonary tumor was exclusively detected by EUS-B. Adding EUS-B to conventional bronchoscopy and EBUS increased the diagnostic yield for diagnosing lung cancer in paraesophageally located lung tumors from 51 to 91%. No EUS-B-related complications were observed. Conclusion: EUS-B-FNA is a feasible and safe technique for diagnosing centrally located intrapulmonary tumors that are located near or adjacent to the esophagus. EUS-B should be considered in the same endoscopy session following nondiagnostic bronchoscopy and EBUS.
Introduction
Lung cancer is the leading cause of cancer-related mortality worldwide [1] . In patients with suspected lung cancer, a tissue diagnosis is crucial to establish a definite diagnosis. However, for patients presenting with a centrally located lung tumor without endobronchial abnormalities and not near the major airways, obtaining a tissue diagnosis is a diagnostic challenge.
In routine practice, flexible bronchoscopy with its associated procedures (endobronchial biopsy, brushing, and washing) is performed, especially in case of a visible endobronchial tumor. However, frequently, no endobronchial abnormalities are visible and in these situations, the diagnostic yield by standard bronchoscopic techniques is low [2] [3] [4] [5] [6] . Guidance techniques (radial endobronchial ultrasound [EBUS]/fluoroscopy, navigation) can be helpful in peripherally located lung lesions in case an airway leads to the tumor but often do not contribute to the diagnostic yield of these specific central lesions [7, 8] .
If the tumor is located near or adjacent to the large airways, endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) is a useful and safe procedure to obtain a tissue diagnosis [9, 10] .
With gastrointestinal endoscopes it has been proven that lung tumors located near or adjacent to the esophagus can be detected and aspirated with esophageal ultrasound (EUS) [11] . However, this technique is not commonly available in most pulmonary practices. Current lung cancer staging guidelines recommend endoscopic ultrasound bronchoscopy (EUS-B) (using the EBUS scope in the esophagus) for mediastinal staging, because this is complementary to EBUS for mediastinal nodal staging [12] [13] [14] [15] . EBUS and EUS-B are also suggested in this guideline for the analysis of lung tumors in patients with a centrally located lung tumor that are not visible with conventional bronchoscopy, provided that the tumor is located immediately adjacent to the larger airways (EBUS-TBNA) or esophagus (EUS-B/ EUS) [16] .
To date, however, there is only limited evidence of the value of endoscopic ultrasound with bronchoscope-guided fine needle aspiration (EUS-B-FNA) for obtaining a tissue diagnosis in centrally located lung tumors [17, 18] . Therefore, we conducted this study to assess the feasibility and diagnostic yield of EUS-B in paraesophageally located lung tumors and its added value to bronchoscopy and EBUS.
Methods

Study Design and Patients
This is a retrospective multicenter international study undertaken in the Naestved Hospital, Naestved, Denmark (Department of Internal Medicine), the Zealand University Hospital, Roskilde, Denmark (Department of Internal Medicine), and in the Academic Medical Center (Department of Respiratory Medicine, University of Amsterdam), Amsterdam, the Netherlands, during the period of January 1, 2015 until January 1, 2018. Patient data were retrieved for the various endosonography databases in the 3 hospitals based on the following criteria: patients who underwent an EUS-B-FNA to obtain a tissue diagnosis of an intrapulmonary lesion for suspected lung cancer and also routinely underwent bronchoscopy and EBUS.
Patient Selection
All patients in whom the paraesophageally located lung tumor was detected by EUS-B and sampled were identified. The presented case is an example of the patient selection (Fig. 1) . All CT and PET-CT imaging, bronchoscopy, EBUS, EUS-B reports, cytopathological reports and follow-up data were collected. Also, complications of EUS-B were retrieved.
Study Endpoints
The primary endpoints of this study were to assess the diagnostic yield of EUS-B and its added value to conventional bronchoscopy and EBUS for obtaining a tissue diagnosis of centrally located lung tumors located near or adjacent to the esophagus.
The secondary endpoints were the adequacy of the tissue samples and sensitivity of EUS-B for the diagnosis of a centrally located lung tumor, the feasibility of EUS-B, and EUS-B-related complication for diagnosing an intrapulmonary tumor.
Definitions of Sample Adequacy, Yield, and Sensitivity
Biopsies were judged to be adequate when containing material sufficient for cytopathological evaluation. Samples in which cytopathological evaluation showed malignancy were considered to be true positive.
When cytopathological evaluation of EUS-B-FNA samples showed no malignancy, the EUS-B diagnosis of the lung lesion was confirmed with at least 6 months of follow-up with clinical course and/or CT. For the calculation of the yield and sensitivity of malignancy, samples with a nonmalignant diagnosis without followup were assumed to be false negative in the analyses (worst case scenario).
The diagnostic yield was defined as the number of samples in which EUS-B-FNA provided a correct diagnosis relative to the total number of samples assessed with EUS-B-FNA [11] .
Sensitivity of malignancy was defined as the number of samples in which EUS-B-FNA diagnosed any malignancy relative to the total number of samples where the targeted intrapulmonary tumor turned out to be malignant [11] .
The EUS-B Procedure
Procedures were performed under conscious sedation using midazolam/fentanyl or propofol sedation. Following a conventional bronchoscopy, systematic EBUS was performed according to EBUS-STAT [19] . Following EBUS, the EUS-B procedure will be discussed in more detail: for EUS-B-FNA, a flexible EBUS endoscope (Olympus BF-UC180F or UC 180F, Olympus Medical Systems Europe, Ltd., Hamburg, Germany, or Pentax EB-1970 UK, Olympus BF-UC180F) was used.
The EBUS endoscope was introduced into the esophagus by retracting the EBUS scope from the trachea to a level just above the vocal cords and from this position turning it slightly to the left and the back of the patient and advancing it into the esophagus under gentle pressure while the patient was encouraged to swallow (in case of mild sedation). The endoscope was advanced carefully till the liver was visualized on ultrasound imaging.
A structured EUS assessment was performed using the esophageal assessment tool (EUS-AT) with 6 landmarks identified in this order: the liver, the abdominal aorta, the left adrenal gland, lymph node station 7, station 4L and 4R. This validated and systematic assessment tool is specifically developed for the examination of lung cancer patients [20] . Following the identification of the intrapulmonary tumor, aspirates were performed using a 21-G or a 22-G needle (22 Gauge Olympus ViziShot and ViziShot 2, Olympus Medical Systems Europe, Ltd., Hamburg, Germany, or a 21-to 22-G COOK needle). When the needle was placed in the lesion under ultrasonic guidance, the stylet was removed, and suction was applied, or the stylet was removed using the slow pull technique. At least two samples were taken. The aspirates were processed for both cytological smears and cellblock analysis. A chest-X-ray was not performed routinely after the procedure.
Statistics
Data were nonparametric and presented with median and range. Data were processed using SPSS (IBM SPSS Statistics, version 22. Chicago, IL, USA).
Ethics
This retrospective analysis was conducted in accordance with the amended Declaration of Helsinki and publication of the data was approved by the Data Protection Agency in Denmark and the medical ethics committee in the Netherlands.
Results
Fifty-eight patients were identified who underwent EUS-B-FNA for diagnosing an intrapulmonary tumor between January 1, 2015 and January 1, 2018. Patient characteristics are shown in Table 1 . Of the 58 patients, 34 were female (59%) with a median age of 78 years. The aspirated lesions were localized in all lobes, with a median size of 55 mm. No EUS-B-related complications were observed.
Final diagnoses were: non-small cell lung cancer (n = 43; adenocarcinoma n = 26; squamous cell carcinoma n = 12; non-small cell lung cancer not otherwise specified n = 5), small cell lung cancer (n = 6), malignant mesothelioma (n = 2), and metastasis from extrapulmonary cancer (n = 1, anal squamous cell carcinoma). In 6 patients, the diagnosis was nonmalignant (unspecific lesion; n = 1, infectious cause n = 5; Table 1 ). Fifty-three patients (91%) had a bronchoscopy and EBUS-TBNA was performed in the same session as EUS-B. Five patients did not undergo bronchoscopy or EBUS due to respiratory problems (n = 2) or the endobronchial procedure was expected to be of little consequence in obtaining a tissue diagnosis (n = 3) due to the anatomical position of the lung lesion.
At bronchoscopy, in 14 patients (24%), the tumor was visualized and biopsied. All these samples showed a malignancy. The diagnostic yield of the bronchoscopy was 26%. Another 14 patients (22%) underwent an EBUS. Thirteen of the samples obtained with EBUS were adequate for cytopathological evaluation; in 11 cases, the samples showed malignancy, in 2 patients the aspirates were nonmalignant (1 showed a necrotizing granulomatous inflammation consistent with tuberculosis and 1 showed a reactive and inflammatory changes at cytopathology with a clinical picture of pneumonia and full regression on antibiotic treatment). The diagnostic yield of EBUS alone was 25%. Adding EBUS to the bronchoscopy raised the diagnostic yield from 26 to 51%. In 1 (2%) case, the tumor could be visualized but not biopsied with EBUS-TBNA.
All 58 patients underwent EUS-B; of these, 52 were diagnostic and 47 were diagnosed to be malignant. In 26 patients (45%), the tumor was exclusively visualized and biopsied with EUS-B-FNA. The diagnostic yield for EUS-B alone was 90%. Combining bronchoscopy, EBUS, and EUS-B resulted in a diagnostic yield of 91% (Fig. 2) .
Of all the 58 samples included in the analysis, 55 (95%) samples were adequate. Of these, 85% (n = 47) were malignant and 15% (n = 8) were nonmalignant. Of these, 4 cases had a clinical and radiological follow-up for at least 6 months, the causes were infectious, and 1 case had the results confirmed in repeated EUS-B-FNA and follow-up CT (2 samples with reactive and inflammatory changes at cytopathology with confirmed microbiologic agents or full regression on antibiotic treatment, 2 samples showed necrotizing granulomatous inflammation consistent with tuberculosis and one sample showed inflammatory cells confirmed at re-examination). These 5 cases are considered true negative. In the 3 other cases, follow-up was not clinically relevant as the patients had the procedure performed on suspicion of relapse of lung cancer, and relapse in mediastinal or neck lymph nodes was found. These cases were considered false negative. (10) 18 (31) 1 (2) 13 ( Of the 3 (5%) inadequate samples, 2 cases had diagnostic adequate samples performed with bronchoscopy or ultrasound-guided transthoracic needle aspiration in the same session as the EUS-B that showed malignancy. One lesion was followed with CT and showed regression of the lesion in 6 months. All 3 cases were considered false negative. Thus, a total of 52 lesions were considered as malignant.
Transthoracic needle aspiration biopsy was performed and was ultrasound guided in the same session as endoscopic procedures in 4 (7%) cases to obtain the final diagnosis; in 1 of these, the diagnosis was only established with transthoracic needle aspiration biopsy.
The sensitivity of EUS-B for diagnosing any malignancy was 90% in this very selected population.
Discussion
In this study, we evaluated the largest series (n = 58) of patients who underwent an EUS-B-FNA for diagnosing a centrally located lung tumor adjacent to the esophagus. We found that EUS-B is safe and has a high diagnostic yield and sensitivity (90%) for diagnosing malignancy. Adding EUS-B to a previous nondiagnostic bronchoscopy and EBUS raised the diagnostic yield from 51 to 91%.
Only one report described EUS-B for diagnosing centrally located lung tumors. Steinfort et al. [17] showed in a small selected cohort study that in 26 out of 27 patients EUS-B was diagnostic. In this study, 10 lesions were inaccessible for bronchoscopic sampling and 9 lesions were inaccessible for EBUS-TBNA. Diagnoses were obtained in predominantly upper lobes and 1 pneumothorax occurred. The current study shows that lung tumors located in all different lobes can be visualized and biopsied safely with EUS-B. In a systematic review and meta-analysis for diagnosing intrapulmonary lung tumors by EUS using the gastrointestinal endoscope, Korevaar et al. [11] showed an average yield of 0.90 and an average sensitivity of 0.92. The complication rate was low with 2%. Our findings show similar results, indicating that tumor sampling by EUS-B lead to similar results as the conventional EUS scope. The potential advantages of the gastrointestinal EUS scope are the following: the larger overview (120-180° depended on the scope manufacturer vs. 60° visualization of EBUS), the needle length (10 vs. 6 cm), the slightly superior ultrasound quality (due to the increased amount of ultrasound crystals of the EUS transducer), and the increased stiffness of the scope. However, in clinical practice, all of the abovementioned items were rated not significant and not a limiting factor for the diagnostic yield of the EUS-B approach.
An advantage of using EUS-B instead of convention gastrointestinal EUS scope for diagnosing lung tumors is that the whole diagnostic and staging procedure can be performed in a single endoscopy session performed by one operator. In our study, 91% of the patients also underwent a conventional bronchoscopy and EBUS in the same session and mediastinal staging was performed in this single session. However, in 45% of the patients, the lung tumor was only detected and biopsied by EUS-B showing the benefit of this transesophageal approach.
An additional advantage of EUS-(B) is that it can be helpful in assessing mediastinal tumor invasion (T4). We have shown that in patients with paraesophageally located lung tumor the EUS assessment (presents absences of mediastinal tumor invasion) has added important value to the CT scan of the chest [21] .
Although CT-guided transthoracic needle aspirations for centrally located parabronchial lesions can be technically undertaken, the significant drawbacks are a high risk of pneumothorax and hemoptysis [16] . In addition, the diagnostic yield is lower than for peripheral lesions [10, 22, 23] .
It should be noted that several limitations apply to this study. First the retrospective character of this study means that there is a large bias of patient selection and the data should be interpreted accordingly. Second, this study analyzed data from 3 centers with expert EUS-B operators. It remains unclear if less experienced endoscopists can achieve similar results. Third visualization of intrapulmonary tumors from the esophagus is only possible if the tumor is located near or adjacent to the esophagus. The maximum distance from the tumor to the esophagus is unknown. In the present study, virtually all tumors were located adjacent to the esophagus. Whether a specific air space between the wall of the esophagus and the lung tumor (as seen on the CT) still allows lung tumor detection by EUS-B needs to be investigated. As the esophagus is located in the left posterior chest, this most often applies to central located leftsided tumors.
Future studies should include larger cohorts in a prospective consecutive design. Our results provide further support that pulmonologists staging lung cancer should be trained in EUS-B-FNA [10] .
Conclusion
EUS-B-FNA is a feasible and safe technique for diagnosing centrally located intrapulmonary tumors that are located near or adjacent to the esophagus. EUS-B should be considered in the same endoscopy session following a nondiagnostic bronchoscopy and EBUS.
